

## Technology Advisory Interests Register

**Topic: Vorasidenib for treating astrocytoma or oligodendroglioma with IDH1 or IDH2 mutations after surgery in people 12 years and over [ID6407]**

**Publication Date: TBC**

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
Emtiyaz Chowdhury	HST Committee Member	Non-Financial Professional	Emtiyaz is employed by Parexel. Parexel offers services to Immedica. They have not been directly involved with any work related to this technology.	18/09/2025 20/11/2025	It was agreed that Emtiyaz's declaration would not prevent them from participating in discussions on this evaluation.
Natalia Kunst	HST Committee Member	Non-Financial Professional	Natalia worked as an EAG for vorasidenib.	18/09/2025 20/11/2025	It was agreed that Natalia's declaration would prevent them from participating in discussions on this evaluation.
Hugh Adams	Patient Expert	Direct – non-financial	Hugh works for a brain tumour charity.	18/09/2025 20/11/2025	It was agreed that Hugh's declaration would not prevent them from providing expert advice to the committee.
Keyoumars Ashkan	Clinical Expert	Indirect	Keyoumars was the chief investigator for an immunotherapy trial for high grade gliomas	18/09/2025 20/11/2025	It was agreed that Keyoumars' declaration would not prevent them

<b>Name</b>	<b>Role with NICE</b>	<b>Type of interest</b>	<b>Description of interest</b>	<b>Interest declared</b>	<b>Comments</b>
			(completed a few years ago). The trial was of a different immunotherapy product produced by a different company		from providing expert advice to the committee.

DRAFT